Search Results - Cardiovascular%2c+Renal%2c+%26+Metabolism

9 Results

Sort By:

Project ID: D2010-12 Background Diabetes mellitus is a disease in which an individual has difficulty regulating their blood glucose levels, in which extremely low or high glucose concentrations can occur. Normal physiological blood glucose ranges are generally between 80-120 mg/dL; however, diabetics commonly have blood concentrations from 50-500...

Inducing plasticity to prime immune system for CAR-Treg therapy

Project ID: D2022-28 Background Regulatory T cells (Tregs) are the critical regulators of peripheral immune tolerance; when defective, Tregs can lead to autoimmune disorders, such as Type 1 Diabetes (T1D) A more recent approach to prevent/treat autoimmunity is to refit immune cells towards their non-inflammatory phenotype in the affected organ. Chimeric...

Pressure Ulcer Boot

Project ID: D2022-32 Background Pressure ulcers or bedsores form when there is a loss of circulation due to prolonged pressure at a point, such as on the heel of the foot. This occurs in immobile patients, such as those confined to a bed or wheelchair. A common way to prevent pressure ulcers is to change the position of the patient with...

One Step Aortic Puncher

Project Id: D2022-31 Background Patients with coronary artery disease develop this disease often over a course of decades. Deposits high in cholesterol, commonly referred to as plaque, builds up in the coronary arteries causing inflammation. This disease tends not to be noticeable until significant blockage or a heart attack occurs. Coronary bypass...

Cofilin inhibitor for the treatment of hemorrhagic brain injury-induced inflammation

Project ID D2019-35 Background Cofilin regulates actin filament assembly and organization in most cells, including during macrophage, T-cell, and dendritic activation and migration. Over-activation of cofilin can lead to microglia inflammation in the brain. Although Cofilin has been shown to be involved in the secondary injury of intracerebral hemorrhage...

PEGylated Bilirubin for the treatment of Hyperlipidemia, Obesity, and Type II Diabetes

Project ID: D2018-40 Background: Obesity, a low-grade inflammatory disease, has affected more than 150 million people in the US. Obesity and its associated risk factors are a prelude to the development of type II diabetes that accounts for a vast majority of the 25.8 million diabetes cases in the US. Bilirubin, a yellow pigment produced during...

Spontaneous Type I Diabetes Mouse Model

Project ID: D2015-60 Background Although the NOD mouse is the current standard for studies of type I diabetes (T1D), no curative therapies resulting from this model have passed clinical trials. Knock in/out models cannot be used to mimic the total pathophysiology of diabetes. In order to develop a cure for T1D, there is a need for an animal model...

Use of Small Molecule Inhibitors as Anti-Thrombotic Agents

ont-size:12px">Project ID: D2016-03 Background Various ailments, including systemic lupus erythematosus (SLE), rheumatoid arthritis and certain cancers can cause a person to suffer a thrombotic event. There are various therapies currently used for treating pro-thrombotic platelets, including molecules that can be divided into families based on mechanism...

“Thin” Molecules for Treating Obesity and Type II Diabetes

Project ID: D2016-29 IP Status: PCT patent application filed Invention Description and Novelty: “Thin” molecules offer stronger binding to PPAR and include greater lipid burning and glucose lowering properties. Applications: Dyslipidemia, obesity and type II diabetes Value propositions: • Bilirubin reduces body...